|
The role of c-Maf in Stem cells in Leukemia
|
1F31CA162770-01
|
$41,800
|
Okoye, Ujunwa
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
EASTERN COOPERATIVE ONCOLOGY GROUP
|
5U10CA014958-37
|
$99,689
|
Sparano, Joseph
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-22
|
$406,165
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
Virginia Mason Community Clinical Oncology Program
|
2U10CA035192-27A1
|
$569,700
|
Nichols, Craig
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
Eastern Cooperative Oncology Group
|
5U10CA080775-13
|
$95,412
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Heat shock proteins in signaling and cancer
|
5R01CA081244-13
|
$344,929
|
SHERMAN, MICHAEL
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Regulation of c-myc translation by hnRNP A1: role in multiple myeloma tumor respo
|
5R01CA132778-03
|
$264,964
|
GERA, JOSEPH
|
BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE
|
|
To establish the BC Cancer Agency - Vancouver Centre as a major SWOG centre
|
5U10CA142559-02
|
$188,304
|
BLANKE, CHARLES
|
BRITISH COLUMBIA CANCER AGENCY
|
|
Carle Cancer Center Community Clinical Oncology Program
|
5U10CA035195-28
|
$794,063
|
ROWLAND, KENDRITH
|
CARLE FOUNDATION
|
|
Eastern Cooperative Oncology Group Studies
|
5U10CA014548-37
|
$386,252
|
AVERBOOK, BRUCE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Cedar Rapids Oncology Project
|
5U10CA052352-22
|
$240,835
|
Wilbur, Deborah
|
CEDAR RAPIDS ONCOLOGY PROJECT
|
|
Delaware/Christiana Care CCOP
|
5U10CA045418-25
|
$1,147,220
|
Grubbs, Stephen
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
City of Hope Southwest Oncology Group Clinical Trials
|
5U10CA046368-24
|
$349,765
|
MORTIMER, JOANNE
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
CCOP: Colorado Cancer Research Program
|
5U10CA067753-16
|
$1,008,553
|
Pajon, Eduardo
|
COLORADO CANCER RESEARCH PROGRAM, INC.
|
|
Multiple Myeloma and Cancer Therapies via Largazole Analogs
|
5R01CA152314-02
|
$305,666
|
WILLIAMS, ROBERT
|
COLORADO STATE UNIVERSITY-FORT COLLINS
|
|
Determinants and risks of use and overuse of expensive oncology drugs
|
5R01CA134964-04
|
$252,995
|
HERSHMAN, DAWN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Columbus Community Clinical Oncology Program (Columbus CCOP)
|
5U10CA035261-28
|
$805,100
|
KUEBLER, J
|
COLUMBUS COMMUNITY CLINICAL ONCOLOGY PRG
|
|
Host-tumor cell interaction in myeloma: therapeutic applications
|
5P01CA078378-12
|
$1,984,614
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INSTITUTE
|
|
SPORE in Myeloma
|
5P50CA100707-09
|
$2,185,000
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INSTITUTE
|
|
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications
|
5R01CA050947-19
|
$278,781
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-46S5
|
$11,164,583
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-46S6
|
$75,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
Selective Inhibition of HDAC6 in Cancer Therapy
|
5K08CA128972-04
|
$139,320
|
BRADNER, JAMES
|
DANA-FARBER CANCER INSTITUTE
|
|
Mining B-catenin/BCL9 transcriptional complex for Multiple Myeloma therapeutics
|
5R01CA151391-02
|
$346,193
|
CARRASCO, RUBEN
|
DANA-FARBER CANCER INSTITUTE
|
|
The role of miRNA15a and 16-1 in Multiple Myeloma
|
1R01CA154648-01A1
|
$363,125
|
Ghobrial, Irene
|
DANA-FARBER CANCER INSTITUTE
|
|
CXCR4 regulation of tumor progression in Multiple Myeloma
|
5R01CA125690-04
|
$311,085
|
Ghobrial, Irene
|
DANA-FARBER CANCER INSTITUTE
|
|
Targeting cell trafficking as a new therapeutic modality for Multiple Myeloma
|
5R01CA133799-04
|
$343,498
|
Ghobrial, Irene
|
DANA-FARBER CANCER INSTITUTE
|
|
ECOG Statistical Office
|
5U10CA023318-35
|
$2,311,793
|
GRAY, ROBERT
|
DANA-FARBER CANCER INSTITUTE
|
|
Differentiating Agents in Hematologic Malignancies
|
5R01CA042802-24
|
$323,814
|
KUFE, DONALD
|
DANA-FARBER CANCER INSTITUTE
|
|
Integrated Analysis of High Throughput Cancer Genomic Data
|
1R21CA157219-01A1
|
$225,327
|
LI, YI
|
DANA-FARBER CANCER INSTITUTE
|
|
Integrative Oncogenomics of Multiple Myeloma
|
1P01CA155258-01
|
$2,000,000
|
MUNSHI, NIKHIL
|
DANA-FARBER CANCER INSTITUTE
|
|
Homologous Recombination Mediates Genomic Instability and Progression in Myeloma
|
5R01CA124929-04
|
$344,180
|
MUNSHI, NIKHIL
|
DANA-FARBER CANCER INSTITUTE
|
|
Cancer Center Support Grant
|
5P30CA023108-33
|
$3,125,750
|
ISRAEL, MARK
|
DARTMOUTH COLLEGE
|
|
Different active sites of the proteasome as drug targets in cancer
|
5R01CA124634-05
|
$265,226
|
Kisselev, Alexei
|
DARTMOUTH COLLEGE
|
|
Dayton Clinical Oncology Program
|
5U10CA035090-29
|
$945,951
|
Gross, Howard
|
DAYTON CLINICAL ONCOLOGY PROGRAM
|
|
CENTRAL ILLINOIS COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
5U10CA045807-26
|
$1,251,900
|
WADE, JAMES
|
DECATUR MEMORIAL HOSPITAL
|
|
Eastern Cooperative Group Chair's Office
|
3U10CA086802-13S1
|
$2,561,235
|
COMIS, ROBERT
|
DREXEL UNIVERSITY
|
|
Eastern Cooperative Group Chair's Office
|
5U10CA086802-13
|
$629,400
|
COMIS, ROBERT
|
DREXEL UNIVERSITY
|
|
Proteosome inhibitor sensitivity in multiple myeloma: The role of ER stress
|
5R01CA127910-05
|
$311,976
|
BOISE, LAWRENCE
|
EMORY UNIVERSITY
|
|
Arsenic-induced apoptosis in myeloma
|
5R01CA129968-03
|
$362,853
|
BOISE, LAWRENCE
|
EMORY UNIVERSITY
|
|
Emory Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-03S1
|
$48,306
|
Curran, Walter
|
EMORY UNIVERSITY
|
|
Emory Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-03S2
|
$75,000
|
Curran, Walter
|
EMORY UNIVERSITY
|
|
Emory Winship Cancer Institute Cancer Center Support Grant
|
5P30CA138292-03
|
$1,356,978
|
Curran, Walter
|
EMORY UNIVERSITY
|
|
Duluth Community Clinical Oncology Program
|
7U10CA035269-28
|
$705,338
|
Nikcevich, Daniel
|
ESSENTIA INSTITUTE OF RURAL HEALTH
|
|
EORTC HEADQUARTERS
|
2U10CA011488-41
|
$232,518
|
SYLVESTER, RICHARD
|
EUROPEAN ORG/RES/TREATMENT/CANCER
|
|
Development of small molecule inhibitor of Mcl-1 for cancer treatment
|
3R44CA135915-02A1S1
|
$321,958
|
CARDONE, MICHAEL
|
EUTROPICS PHARMACEUTICALS, INC.
|
|
Development of small molecule inhibitor of Mcl-1 for cancer treatment
|
5R44CA135915-03
|
$971,831
|
CARDONE, MICHAEL
|
EUTROPICS PHARMACEUTICALS, INC.
|
|
North Shore CCOP
|
5U10CA035279-28
|
$599,459
|
VINCIGUERRA, VINCENT
|
FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
|
|
Community Clinical Oncology Program: FL Pediatric CCOP
|
5U10CA035157-28
|
$450,001
|
TALBERT, JAMES
|
FLORIDA ASSN OF PEDIATRIC TUMOR PROG
|
|
Eastern Cooperative Oncology Group
|
5U10CA027525-33
|
$408,206
|
GOLDSTEIN, LORI
|
FOX CHASE CANCER CENTER
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|